share_log

BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Attacks In Adults And Pediatric Patients 12 Years

BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Attacks In Adults And Pediatric Patients 12 Years

BioCryst Pharmicalst 宣佈，巴西衛生監管機構已批准口服、每日一次的ORLADEYO（Berotralstat），用於預防12年成人和兒科患者的遺傳性血管性水腫（Hae）發作
Benzinga ·  04/17 16:36

BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Attacks In Adults And Pediatric Patients 12 Years

BioCryst Pharmicalst 宣佈，巴西衛生監管機構已批准口服、每日一次的ORLADEYO（Berotralstat），用於預防12年成人和兒科患者的遺傳性血管性水腫（Hae）發作

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論